# IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors

> **NCT05958121** · PHASE1,PHASE2 · RECRUITING · sponsor: **Immatics Biotechnologies GmbH** · enrollment: 145 (estimated)

## Conditions studied

- Refractory Cancer
- Recurrent Cancer
- Solid Tumor, Adult
- Cancer

## Interventions

- **BIOLOGICAL:** IMA402 (Phase Ia)
- **BIOLOGICAL:** IMA402 (Phase Ib)
- **BIOLOGICAL:** IMA402 (Phase II)

## Key facts

- **NCT ID:** NCT05958121
- **Lead sponsor:** Immatics Biotechnologies GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-09
- **Primary completion:** 2027-09
- **Final completion:** 2027-09
- **Target enrollment:** 145 (ESTIMATED)
- **Last updated:** 2025-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05958121

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05958121, "IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05958121. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*